AzTrials
AzTrials

StrokeNCT02879279

Multi-segmental Robotic and Technological Upper Limb Rehabilitation in Stroke

A study testing Amadeo, Pablo, Diego and Motore. and Conventional rehabilitation in people with Stroke, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Stroke is frequently associated with significant disability and impaired quality of life. Persistent motor impairment is common with often incomplete recovery of motor function in response to rehabilitation, mainly in the upper limbs. Read more about this study

Who is it for?
Ages 40 to 80 years
Conditions the study is for
Stroke
What is being tested?
Amadeo, Pablo, Diego and Motore. and Conventional rehabilitation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
247 participants
Where
1 siteItaly
Study dates
May 2016to Mar 2018
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Acute or sub-acute patients, with ischemic and hemorrhagic stroke, verified by MRI or CT
  • Age between 40 and 80 years;
  • Time latency since stroke ranging from two weeks to six months
  • Cognitive and language abilities that are sufficient to understand the experiments and follow instructions

Who cannot join

  • Behavioral and cognitive disorders and/or reduced compliance that would interfere with active therapy;
  • Fixed contraction deformity in the affected limb that would interfere with active therapy (ankylosis, Modified Ashworth Scale = 4);
  • Severe deficits in visual acuity;
  • Upper extremity Fugl-Meyer score >58.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • Don Gnocchi Foundation

    Rome, 00168

Other trials in Italy

About this study

Official title: Efficacy of a Multi-segmental Robotic and Technological Upper Limb Rehabilitation Program, Compared With Traditional Therapy, in Individuals With Acute and Sub-acute Stroke: a Multicenter, Randomized, Controlled Clinical Trial.

Stroke is frequently associated with significant disability and impaired quality of life. Persistent motor impairment is common with often incomplete recovery of motor function in response to rehabilitation, mainly in the upper limbs. Robot-mediated therapy has been proposed as a viable approach for the rehabilitation of the upper limb, but as the evidence quality is low, more rigorous studies are needed. Previous studies have focused on the effects of devices acting on a limited number of joints, often limiting the workspace on a plane. This study aims to evaluate the efficacy of a multi-set of robotic and technological devices for the rehabilitation of the upper limb in sub-acute stroke patients.

Read the detailed description

Stroke is the first cause of disability in the world, with a very high social impact. Recovery is partial in 85% of stroke survivors, 35% of whom have a persisting serious disability. The increase in lifespan is leading to a rise in the incidence of stroke, and therefore to a rise in the number of people requiring a rehabilitation program. Rehabilitation programs are mainly focused on walking recovery, with insufficient attention being paid to upper limb recovery. Thirty to 60% of patients treated with conventional therapy present functional deficits of the paretic arm, resulting in an impairment of activities of daily living.

Robot-mediated therapy (RT) has been proposed in the literature as a viable approach for the rehabilitation of the upper limb. A first meta-analysis of 262 subjects showed that when the duration/intensity of conventional therapy (CT) is matched with that of the robot-assisted therapy, no difference exists between the two groups in terms of motor recovery, activities of daily living, strength or motor control; instead, when the RT is added to CT, a greater effectiveness can be observed, when compared with regular CT alone (5). A subsequent meta-analysis by Mehrholz et al., including 19 trials (involving 666 subjects), showed that RT was more effective than other interventions in improving patients' activities of daily living (SMD 0.43, 95% confidence interval (CI) 0.11 to 0.75, P = 0.009, I2 = 67%). In the same sample, stratified by time since disease onset, the analysis confirmed that RT was more effective in improving the activities of daily living in the 224 acute and sub-acute patients (within 3 months of stroke onset) (SMD 0.64, 95% CI 0.14 to 1.15, P=0.01, I2 =69%). The same findings were not confirmed in 334 chronic patients (more than 3 months after stroke) (SMD 0.85, 95% CI -0.27 to 1.97, P=0.14, I2 =94%). As for the other outcomes, robotic therapy was more effective in improving upper extremity function (SMD 0.45, 95% CI 0.20 to 0.69, P = 0.0004, I2 = 45%), but not muscular strength (SMD 0.48, 95% CI -0.06 to 1.03, P = 0.08, I2 = 79%). Finally, RT was well accepted by patients, there was no marked increase in the number of drop-outs, and serious adverse events were rare and unrelated to the robotic treatment (6).

In an update of their meta-analysis, published in 2015, the same research team confirmed that RT was more effective than other therapies in improving activities of daily living (SMD 0.37, 95% confidence interval (CI) 0.11 to 0.64, P = 0.005, I² = 62%), motor function (SMD 0.35, 95% CI 0.18 to 0.51, P < 0.0001, I² = 36%) and strength (SMD 0.36, 95% CI 0.01 to 0.70, P = 0.04, I² = 72%) of the upper limb. RT was well accepted by patients, there was no marked increase in the number of drop-outs (RD 0.00, 95% CI -0.02 to 0.03, P = 0.84, I² = 0%), and serious adverse events were rare and unrelated to the robotic treatment. However, the authors concluded that the evidence quality was low, highlighting the need for more rigorous studies.

It should be noted that the authors of the review highlighted the fact that the studies reviewed were heterogeneous in terms of study design (two arms, four arms, parallel groups or cross-over, duration of follow-up and selection criteria), of the devices used for the therapeutic treatment, of the patients' characteristics (time since disease onset), of the methodological protocols (methods of randomization, of the blindness of the outcome assessors to group allocation, and of the presence or absence of an intention to treat analysis).

However, the authors emphasized that limitations such as the inability to blind the therapist and participants, i.e. the so-called contamination (provision of the intervention to the control group), and co-intervention (when the same therapist unintentionally provides additional care to either treatment or comparison group) has often been present in rehabilitation studies. Moreover, they pointed out that sometimes the sample is selected according to comorbidities, age, spasticity or pain; instead, in clinical practice patients are often older, and the prevalence of comorbidity, pain, spasticity and/or limitations of articular function is higher than that reported in the studies analyzed. Therefore, inclusion criteria that allow the effects of a robotic treatment to be evaluated on a larger sample of patients with stroke, with clinical characteristics as close as possible to the real-world clinical setting, are desirable.

Many authors have highlighted the impact on costs and the greater sustainability of the RT when compared with the CT. The latter requires a ratio of one therapist to one patient, while RT, after adequate training of the therapist, allows a ratio of one therapist to every three or four patients, depending on the technology used.

RT allows patients' improvements to be assessed even after a single treatment session, to constantly monitor the rehabilitation program and therefore to better define the best rehabilitation strategies. In fact, thanks to the possibility the systems available, it is possible to customize the treatment based on the patients' clinical characteristics. Last but not least, robotic devices involve and motivate patients, providing them with visual and auditory feedback through virtual reality programs in the form of games. Training progresses through increasingly difficult stages that can be linked by patients to their own progress. This becomes an important stimulus to increase the active participation of patients in the rehabilitation program.

Almost all scientific papers in the literature have focused on the effects of the use of one or, at most, two robotic devices, compared with a conventional approach.

However, even though the anatomy and the motor function of the upper limbs, especially the hand, is extremely complex, all but a very few commercial devices act on a limited number of joints and limit the workspace on a plane. By contrast, during conventional therapy the whole upper limb is routinely treated and the three-dimensional space, in which the upper limb is normally required to move to accomplish daily activities, is normally explored. In the light of the above, it is very difficult to compare the effects of robotic and traditional approaches.

This results in the need for a multi-set of robots and electromechanical systems, each of which acts on a different joint and/or on a different plane, in upper limb rehabilitation in stroke patients. To the best of our knowledge, the effects of a similar approach, i.e. the use of a multi-set of robotic devices to restore motor function in patients with stroke, have never been compared with those of a conventional approach. Moreover, the effects should ideally be explored on a large sample of subjects that are representative of clinical practice.

Hypothesis. The rationale behind the study is that a multi-set of robotic devices used to treat the whole upper limb may be more effective than conventional treatments in improving upper limb motor performance, since they raise the degree of motivation and participation among patients, and provide a more intensive, standardized and individualized treatment.

Therefore, the investigators wish to verify this hypothesis on a large sample of subjects, within a multicenter study using the same multi-set of robotic devices and the same outcome measures, to obtain better-quality scientific evidence than that currently available in the literature.

Aim: to assess, using evidence-based criteria (RCT), the effectiveness of a rehabilitation program targeting all the upper limb joints in stroke patients, using a multi-set of robotic and technological systems, by comparing it with that of a conventional approach.

Conditions
Stroke
Being tested
Amadeo, Pablo, Diego and Motore., Conventional rehabilitation
Keywords
Stroke, Upper limb, Robotic rehabilitation
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Amadeo, Pablo, Diego and Motore.Device

    In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.

  • Conventional rehabilitationOther

    In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.

Study groups in NCT02879279
Study groupRoleWhat they receive
Robotic rehabilitationExperimentalIn the robotic rehabilitation group, both the distal and the proximal parts of the patients' upper arm will be treated by means of a multi-set of robotic and technological devices, i.e, Amadeo, Pablo, Diego and Motore. The aforementioned systems can be used to perform three-dimensional movements of the shoulder, planar movements of the shoulder and elbow, prono-supination movements of the forearm, flexion-extension movements of the wrist, bimanual movements, and flexion/extension movements of the fingers. A vibratory treatment will be applied, using the Amadeo, to increase the proprioception of the hand. Motor and cognitive tasks, comprising active, passive and active-assistive, will be performed during the treatment. Visual and auditory feedback will be provided to help the patients.
Receives: Device: Amadeo, Pablo, Diego and Motore.
Conventional rehabilitationActive comparatorIn the conventional rehabilitation group, patients will undergo a conventional treatment. The therapeutic tasks will focus on sensorimotor reprogramming, hypertonus inhibition, functional improvement, including task-oriented exercises. Specifically, patients will perform passive, active and active assisted exercises on the three upper limb joints, to improve joint function, to prevent contractures, to inhibit hypertonus and to improve trophism and motor function.
Receives: Other: Conventional rehabilitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline Fugl-Meyer Assessment of Motor Recovery after Stroke (Upper Extremity portion)

    The Fugl-Meyer Assessment is a stroke-specific, performance-based impairment index. It is designed to assess motor functioning, sensation and joint functioning in patients with post-stroke hemiplegia

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

Secondary outcomes (9)
  1. Change from Baseline Motricity Index

    It is a scale to evaluate the motor impairment in a patient who has had a stroke.

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  2. Change from Baseline British Medical Research Council Scale (Shoulder, Elbow and Wrist)

    It is a scale to test muscle strength

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  3. Change from Baseline Modified Ashworth Scale (Shoulder, Elbow and Wrist)

    It is a scale to measure spasticity

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  4. Change from Baseline Frenchay Activities Index

    It is designed to assess functional status in stroke patients

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  5. Change from Baseline Action Research Arm Test

    It is designed to assess upper limb functioning using observational methods

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  6. Change from Baseline Douleur Neuropathique 4

    It is designed to assess pain and to distinguish nociceptive from neuropathic pain

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  7. Change from Baseline Numeric Rating Scale

    It is a scale to assess pain

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  8. Change from Baseline Modified Barthel Index

    It is designed to assess the ability of an individual with a neuromuscular or musculoskeletal disorder to care for him/herself

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

  9. Change from Baseline Short Form-36

    It is a 36 item questionnaire which measures Quality of Life.

    Measured: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Aug 2016 (estimated)
  2. Study startMay 2016
  3. Primary completionMar 2018
  4. Study completionMar 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
247 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02879279
Sponsor's protocol ID
FDG_MUR
Status last verified
Dec 2018
First submitted
11 Aug 2016
Last updated
13 Dec 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. Cochrane Database Syst Rev. 2015 Nov 7;2015(11):CD006876. doi: 10.1002/14651858.CD006876.pub4.

    PubMed 26559225
  • Kwakkel G, Kollen BJ, Krebs HI. Effects of robot-assisted therapy on upper limb recovery after stroke: a systematic review. Neurorehabil Neural Repair. 2008 Mar-Apr;22(2):111-21. doi: 10.1177/1545968307305457. Epub 2007 Sep 17.

    PubMed 17876068
  • Pollock A, Farmer SE, Brady MC, Langhorne P, Mead GE, Mehrholz J, van Wijck F. Interventions for improving upper limb function after stroke. Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD010820. doi: 10.1002/14651858.CD010820.pub2.

    PubMed 25387001
  • Norouzi-Gheidari N, Archambault PS, Fung J. Effects of robot-assisted therapy on stroke rehabilitation in upper limbs: systematic review and meta-analysis of the literature. J Rehabil Res Dev. 2012;49(4):479-96. doi: 10.1682/jrrd.2010.10.0210.

    PubMed 22773253
  • Cecchi F, Germanotta M, Macchi C, Montesano A, Galeri S, Diverio M, Falsini C, Martini M, Mosca R, Langone E, Papadopoulou D, Carrozza MC, Aprile I. Age is negatively associated with upper limb recovery after conventional but not robotic rehabilitation in patients with stroke: a secondary analysis of a randomized-controlled trial. J Neurol. 2021 Feb;268(2):474-483. doi: 10.1007/s00415-020-10143-8. Epub 2020 Aug 25.

    PubMed 32844309
  • Aprile I, Germanotta M, Cruciani A, Loreti S, Pecchioli C, Cecchi F, Montesano A, Galeri S, Diverio M, Falsini C, Speranza G, Langone E, Papadopoulou D, Padua L, Carrozza MC; FDG Robotic Rehabilitation Group. Upper Limb Robotic Rehabilitation After Stroke: A Multicenter, Randomized Clinical Trial. J Neurol Phys Ther. 2020 Jan;44(1):3-14. doi: 10.1097/NPT.0000000000000295.

    PubMed 31834217
  • Germanotta M, Cruciani A, Pecchioli C, Loreti S, Spedicato A, Meotti M, Mosca R, Speranza G, Cecchi F, Giannarelli G, Padua L, Aprile I. Reliability, validity and discriminant ability of the instrumental indices provided by a novel planar robotic device for upper limb rehabilitation. J Neuroeng Rehabil. 2018 May 16;15(1):39. doi: 10.1186/s12984-018-0385-8.

    PubMed 29769127

Questions about this trial

What is this clinical trial studying?

A study testing Amadeo, Pablo, Diego and Motore. and Conventional rehabilitation in people with Stroke, run by Fondazione Don Carlo Gnocchi ETS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline Fugl-Meyer Assessment of Motor Recovery after Stroke (Upper Extremity portion) (time frame: Patients will be evaluated at baseline (T0), at the end of each rehabilitation program (T1), lasting 6 weeks, and 3 months after the end the treatment (T2)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02879279, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Dec 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in